BEERAHEE, M. CLINICAL PHARMACOLOGIST PUBLICATIONS

MIDD as technical writer

1. Chandasana, Hardik; Buchanan, Ann M; Henegar, Cassidy A.; McKenna, Michael; Vavro, Cindy; Puga, Ana ; Brothers, Cindy ; Tan, Lionel; Bush, Mark; Mehta, Rashmi ; Paul, Mary; Lewis, Linda; Ruel, Theodore. Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance. The Pediatric Infectious Disease Journal: February 04, 2026. DOI: 10.1097/INF.0000000000005158. The Pediatric Infectious Disease Journal
2. Mahar, K, Yang, S et al, Model-Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients with Anemia. *Clinical Pharmacology & Therapeutics*, 2025,October. https://doi.org/10.1002/cpt.70094
3. Mahar, K et al, Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney Disease. *Clinical Pharmacology & Therapeutics*, 2025, January, https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.3544
4. Mahar, K.M., Yang, S., Mesic, E., Post, T.M. & Goulooze, S.C. Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia. *Clinical Pharmacokinetics* **63**, 1327-41 (2024). https://doi.org/10.1007/s40262-024-01417-9
5. Chandasana H, Hayes S, Buchanan AM, *et al*; Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics. AIDS. 2024 Jul 15;38(9):F11-F18. https://www.ncbi.nlm.nih.gov/pubmed/38768443
6. Chandasana H, Bush M, Vavro C, Huang J, Ait-Khaled M, Wynne B, Min S, Mehta R. Integrated Population Exposure-Response of Dolutegravir in HIV-1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics. Clin Pharmacol Ther. 2024 Oct;116(4):1100-1109. https://doi.org/10.1002/cpt.3370

MIDD co-author

7. Llanos-Paez, C., Ambery, C., Beerahee, M. et al. Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials. J Pharmacokinet Pharmacodyn (2023). https://doi.org/10.1007/s10928-023-09853-z
8. Malek Okour, Mita M. Thapar, …, and Misba Beerahee. Pediatric Population Pharmacokinetic Modeling and Exposure–Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data, The Journal of Clinical Pharmacology, 2023, 0(0) 1–11. http://dx.doi.org/10.1002/jcph.2199
9. Llanos-Paez, C., Ambery, C., Yang, S. , …, Beerahee, M *et al.* Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients. *Pharm Res* **39**, 1779–1787 (2022).). https://doi.org/10.1007/s11095-022-03194-1
10. Llanos-Paez C, Ambery C, Yang S, Tabberer M, Beerahee M, Plan EL, et al. Improved decision-making confidence using item-based Pharmacometric model: illustration with a phase II placebo-controlled trial. AAPS J. 2021;23:79. https://doi.org/10.1208/s12248-021-00600-1
11. Yang, S., Simeoni, M. and Beerahee, M. (2022), Longitudinal Model-Based Meta-Analysis of Lung Function Response to Support Phase III Study Design in Chinese Patients With Asthma. Clin Pharmacol Ther, 111: 1286-1295. https://doi.org/10.1002/cpt.2578
12. Largajolli, A., Beerahee, M. & Yang, S. Bayesian approach to investigate a two-state mixed model of COPD exacerbations. *J Pharmacokinet Pharmacodyn* **46**, 371–384 (2019). https://doi.org/10.1007/s10928-019-09643-6
13. Germovsek, E., Ambery, C., …, Beerahee, M. *et al.* A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to

EXACT® Daily Diary Data from COPD Patients. *AAPS J* **21**, 60 (2019). https://doi.org/10.1208/s12248-019-0319-9

14. Mehta, R., Pefani, E., Beerahee, M., …, *et al*. (2018), Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD. The Journal of Clinical Pharmacology, 58: 1461-1467. https://doi.org/10.1002/jcph.1253
15. Yang, S., Goyal, N., Beerahee, M. *et al.* Dose–response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma. *Eur J Clin Pharmacol* **71**, 1051–1058 (2015). https://doi.org/10.1007/s00228-015-1894-z
16. Donohue, J.F., Kalberg, C., Shah, P., Beerahee, M., …, *et al*. (2014), Dose response of umeclidinium administered once or twice daily in patients with COPD: A pooled analysis of two randomized, double-blind, placebo-controlled studies. The Journal of Clinical Pharmacology, 54: 1214-1220. https://doi.org/10.1002/jcph.340
17. Yang, S., Gomeni, R. and Beerahee, M. (2014), Does short-term placebo response predict the long-term observation? Meta-analysis on forced expiratory volume in 1 second from asthma trials. The Journal of Clinical Pharmacology, 54: 1207-1213. https://doi.org/10.1002/jcph.329
18. Marostica, E., Russu, A., Yang, S. Beerahee, M. *et al.* Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response. *J Pharmacokinet Pharmacodyn* **41**, 553–569 (2014). https://doi.org/10.1007/s10928-014-9373-1
19. Goyal, N., Beerahee, M., Kalberg, C. *et al.* Population Pharmacokinetics of Inhaled Umeclidinium and Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. *Clin Pharmacokinet* **53**, 637–648 (2014). https://doi.org/10.1007/s40262-014-0143-4
20. Church, A., Beerahee, M., Brooks, J. *et al.* Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. *BMC Pulm Med* **14**, 2 (2014). https://doi.org/10.1186/1471-2466-14-2
21. Yang, S., Beerahee, M. Losmapimod concentration–QT relationship in healthy volunteers: meta-analysis of data from six clinical trials. *Eur J Clin Pharmacol* **69**, 1261–1267 (2013). https://doi.org/10.1007/s00228-012-1469-1
22. Yang, S., Lukey, P., Beerahee, M. *et al.* Population Pharmacokinetics of Losmapimod in Healthy Subjects and Patients with Rheumatoid Arthritis and Chronic Obstructive Pulmonary Diseases. *Clin Pharmacokinet* **52**, 187–198 (2013). https://doi.org/10.1007/s40262-012-0025-6
23. Yang, S., Beerahee, M. Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug–drug interaction studies. *Eur J Clin Pharmacol* **67**, 225–233 (2011). https://doi.org/10.1007/s00228-010-0957-4

Clinical Pharmacology

24. Malcolm Begg, Augustin Amour, …,Misba Beerahee, et al ; An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome. Pulmonary Pharmacology & Therapeutics, Volume 79, April 2023, 10220, 1-10. https://doi.org/10.1016/j.pupt.2023.102201
25. Divya Mohan, Harry Rossiter, Henrik Watz, …, Misba Beerahee *et al*. Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial. *Thorax* 2023;78:258–266 , https://thorax.bmj.com/content/78/3/258
26. Valerie J. Ludbrook , Kate E. Hanrott , James L. Kreindler , …, Misba Beerahee, *et al*. Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough. *ERJ Open Res 2021*; Vol 7, No 3, 1-11, https://doi.org/10.1183/23120541.00269-2021
27. Sarah Mole, Anya Harry, Andy Fowler, …, Misba Beerahee, *et a*l. Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge. Pulmonary Pharmacology & Therapeutics, Volume 64, 2020 https://doi.org/10.1016/j.pupt.2020.101977

28. Mosteller, Michael; Condreay, Lynn D.; …, Beerahee, Misba*, et al*. Exploring the roles of UGT1A1 and UGT1A3 in oral clearance of GSK2190915, a 5-lipoxygenase-activating protein inhibitor. Pharmacogenetics and Genomics 24(12):p 618-621, December 2014. | DOI: 10.1097/FPC.0000000000000090
29. Holland, C., van Drunen, C., Denyer, J., Smart, K., Segboer, C., Terreehorst, I., Newlands, A., Beerahee, M., Fokkens, W. and Tsitoura, D.C. (2014), Intranasal SB-705498 in humans. Br J Clin Pharmacol, 77: 777-788. https://doi.org/10.1111/bcp.12219
30. Cahn, A., Hodgson, S., …, Beerahee, M. *et al.* Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study. *BMC Pharmacol Toxicol* **14**, 14 (2013). https://doi.org/10.1186/2050-6511-14-14
31. Smith, D.A., Minthorn, E.A. & Beerahee, M. Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody. *Clin Pharmacokinet* **50**, 215–227 (2011). https://doi.org/10.2165/11584340-000000000-00000
32. Misba Beerahee. Clinical pharmacology of atovaquone and proguanil hydrochloride. (1999), Journal of Travel Medicine 6 Suppl 1:S13-7
33. Hussein, Z., Beerahee, M., *et al.* (1999), Pharmacokinetics of the nitric oxide synthase inhibitor L-*N*G-methylarginine hydrochloride in patients with septic shock. Clinical Pharmacology & Therapeutics, 65: 1-9. https://doi.org/10.1016/S0009-9236(99)70116-5
34. Taylor A, *Beerahee A*, *et al*. The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. Br J Clin Pharmacol 1999;47(2):219–22. 10.1046/j.1365-2125.1999.00867.x
35. Taylor, A.C., Beerahee, A., …, et al. (1999), Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L-Dopa in Patients with Parkinson's Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 19: 150-156. https://doi.org/10.1016/S0009-9236(99)70116-5
36. Hamilton, T.C., Beerahee, A., Moen, J.S., *et al.* (1993), Levcromakalim. Cardiovascular Drug Reviews, 11: 199-222. https://doi.org/10.1016/S0009-9236(99)70116-5
37. D.B. Jack, J.L. Hawker, L. Rooney, M. Beerahee, et al. Measurement of the distribution coefficients of several classes of drug using reversed-phase thin-layer chromatography, Journal of Chromatography A, Volume 452, 1988, Pages 257-264, https://doi.org/10.1016/S0021-9673(01)81451-5.
38. Beerahee, M., Wilkins, M.R., Jack, D.B. *et al.* Twelve hour (trough) plasma nifedipine concentrations during chronic treatment with nifedipine retard. *Eur J Clin Pharmacol* **32**, 347–349 (1987). https://doi.org/10.1007/BF00543967
39. Smith, S., Kendall, M., Lobo, J., Beerahee, A., *et al*. (1987), Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration.. British Journal of Clinical Pharmacology, 23: 311-315. https://doi.org/10.1111/j.1365-2125.1987.tb03050.x